Skip to main content

Table 5 HR-HPV distribution of SureX HPV and Venus HPV test results

From: Evaluation of the SureX HPV genotyping test for the detection of high-risk HPV in cervical cancer screening

HPV genotype SureX HPV Venus HPV aSureX+/ SureX+/ SureX−/ SureX−/ Positive agreement (%) Kappar 95% CI
aVenus+ Venus− Venus+ Venus−
HPV 16 144 143 138 6 5 141 92.6 0.924 0.876–0.966
HPV18 28 32 27 1 5 257 81.8 0.889 0.786–0.970
HPV58 26 23 22 4 1 263 81.5 0.889 0.772–0.978
HPV52 18 20 17 1 3 269 81 0.887 0.758–0.976
HPV33 14 13 13 1 0 276 92.9 0.916 0.863–1.00
HPV51 10 9 9 1 0 280 90 0.946 0.775–1.00
HPV66 8 8 7 1 1 281 77.8 0.871 0.594–1.00
HPV35 4 3 3 1 0 286 75 0.855 0.329–1.00
HPV59 6 4 4 2 0 284 66.7 0.797 0.329–1.00
HPV56 7 8 6 1 2 281 66.7 0.795 0.491–1.00
HPV39 10 13 9 1 4 276 64.3 0.696 0.502–0.864
HPV45 5 3 2 3 1 284 33.3 0.493 − 0.862
HPV31 6 7 3 3 4 280 30 0.449 − 0.777
HPV68 4 3 0 4 3 283 0 − 0.012 − 0.025
  1. aSureX: SureX HPV test; Venus:Venus HPV test
  2. Single HPV subtypes and multiple HPV subtypes were calculated together